More Information

Emerging News

Authors: Editor AVP
Publication: Australian Veterinary Practitioner, Volume 55, Issue 1, pp 6, Mar 2025
Publisher: Australian Veterinary Association

Animal type: Dog
Article class: News
Abstract:

There has been significant publicity in North America about potential side effects of bedinvetmab, called LibrelaTM in North America and BeransaTM in Australia. The drug is currently licensed for use in osteoarthritis (OA) in dogs and is considered by some to be the first-line treatment for confirmed chronic OA, where surgical stablisation is not needed.

Access to the full text of this article is available to members of:
  • SciQuest AVP - Personal Subscription
If you're a member or subscriber and believe you should have access:
Login

Otherwise:
Register for an account